Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Summary: Background: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel technology formulated as a low dose vaccine against COVID-19. Methods: A phase I first-in-human dose-ranging trial of a saRNA COVID-19 vaccine candidate LNP-nCoVsaRNA, was conducted at Imperial Clinica...

Full description

Bibliographic Details
Main Authors: Katrina M. Pollock, Hannah M. Cheeseman, Alexander J. Szubert, Vincenzo Libri, Marta Boffito, David Owen, Henry Bern, Jessica O'Hara, Leon R. McFarlane, Nana-Marie Lemm, Paul F. McKay, Tommy Rampling, Yee Ting N. Yim, Ana Milinkovic, Cherry Kingsley, Tom Cole, Susanne Fagerbrink, Marites Aban, Maniola Tanaka, Savviz Mehdipour, Alexander Robbins, William Budd, Saul N. Faust, Hana Hassanin, Catherine A. Cosgrove, Alan Winston, Sarah Fidler, David T. Dunn, Sheena McCormack, Robin J. Shattock
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021005435

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021005435

Similar Items